AIDSVax Field Trial Makes a Splash While Humble Canarypox Phase II Plods Along Uncelebrated AIDS 'end game' While precious little has changed on the HIV vaccine front since last summer, when California-based VaxGen received the go-ahead to proceed with a…
At the Keystone HIV Pathogenesis symposium in January 1999, the Aaron Diamond AIDS Research Center's Douglas F. Nixon presented a paper entitled "Temporary Containment of Viral Replication After Cessation of Antiretroviral Drug Therapy." He reported on 4 individuals from one…
High-Technology Betrays Its Dark Side As Researchers and Patients Struggle to Interpret the Noise 'AIDS is back' When queried about his take on the Chicago retrovirus meeting and the state of HIV clinical care at large, a relatively high-profile-if arriviste-Floridian…
Scottish Scribe Tells of Resistance Testing Success, Superinfection, Flaws in Dual Protease Regimens 'Extensively reprised' In contrast to U.K. Drug Therapy Congresses past, where physician attendance from the U.S. was rife but that of U.S. activists lackluster, this year's late…
Tidy Clinical Science Stares Down Quotidien Chaos Theory; Might Not 'Late, Hard' Be Better After All? 'Irrelevant HAART' As part of an afternoon Glasgow plenary session entitled "Key Issues in Treatment Failure" (Wednesday 11 November 1998, 4th International Congress on…
From Acting Up to Acts of Congress, AIDS Activist Reviews and Critiques a Decade of Social Change Green light, red light at FDA At last month's 4th International Congress on Drug Therapy in HIV Infection (Glasgow, Scotland, U.K.), TAG's Mark…
Deluge of Mutant Coreceptor Discoveries Pave Way for Therapeutic Advances in HIV, Allergy, Arthritis 'Steady stream of papers' With the identification of naturally occurring genetic mutations that can protect against HIV infection and disease progression, academic scientists and pharmaceutical company…
Dutch, U.S. Researchers Report Partial Success with Flushing Strategies; Plan to Suspend Treatment in Patients Halls abuzz with the 'c' word Late every August, the once-and-future greats (and some not-so greats) of AIDS research pay homage to HIV co-discoverer Robert…
Studies of abacavir suggest no distinguishing benefit for abacavir compared to other currently available marketed therapies. The drug is clearly active against HIV in a variety of different patient groups; however, no evidence suggests clinically greater utility than existing nucleoside…
Third Non-Nuke Receives FDA Imprimatur and Promises to Revolutionize Triple Cocktail Mix Teratogenicity remains a concern On Friday September 18, the FDA granted accelerated approval to DuPont Pharmaceuticals' efavirenz, also known as Sustiva, a potent non-nucleoside reverse transcriptase inhibitor which…